FDA Lifts Clinical Hold On Aprea's Relapsed/Refractory Blood Cancer Studies
Aprea Therapeutics Inc (NASDAQ: APRE) can resume testing its eprenetapopt after a string of clinical holds on the therapy in August 2021.
The Company plans to study the drug in new trials across various myeloid and lymphoid malignancies.
Benzinga ·
Benzinga
